While there are some studies that have evaluated the cost-effectiveness of genetic testing, screening and/or prevention in women with elevated risk for breast and/or ovarian cancer, for example, Ashkenazi Jewish women [32] and women with BCRA-1/2 mutation [33, 34] (for a recent review see Sroczynski et al. 2020 [35]), there are currently, only two other studies that have evaluated the cost-effectiveness of different prevention strategies in BRCA-1/2 mutation carriers for the German health care context [21]. This evidence concerns the gene BRCA1 and ovarian cancer.